Cognitive Versus Magnetic Resonance-Ultrasound Fusion Prostate Biopsy: Which One Is Worthier to Perform?. Issue 4 (December 2020)

• Record Type: Journal Article
• Authors: Turkay, Rustu; Inci, Ercan; Yildiz, Omer; Ozgur, Eren; Taşci, Ali İhsan
• Is Part Of: Ultrasound quarterly. Volume 36:Issue 4(2020)
• Publication Date: 2020-12
• Subjects: prostate fusion biopsy -- cognitive fusion biopsy -- MR/US fusion biopsy; Diagnostic ultrasonic imaging -- Periodicals; 616.07543
• DOI: 10.1097/RUQ.0000000000000505
• Languages: English
• ISSNs: 0894-8771

Abstract

Abstract : Abstract: The aim of our study is to compare 2 prostate fusion biopsy models in terms of accurate target sampling. One hundred patients who had Prostate Imaging-Reporting and Data System score 3, 4, or 5 lesions (lesion diameter, >5 mm in long axis) in multiparametric-magnetic resonance imaging and prostate-specific antigen levels between 3 and 10 ng/mL were enrolled in the study. All patients were biopsy naive. Two groups were composed with 50 patients each. Group 1 patients had cognitive fusion (CF) biopsy, and group 2 had magnetic resonance-ultrasound fusion platform biopsy. After fusion biopsy, standard biopsy was also performed. Outcomes of histopathologic and demographic data were evaluated statistically. There were no statistical differences between the 2 groups in terms of age, prostate-specific antigen levels, prostate volume, and lesion length ( P > 0.05). There was no statistically significant difference in sampling targeted lesions ( P > 0.05). Also, no difference was found between the 2 groups in terms of random biopsy cancer detection rates ( P > 0.05). There was no statistically significant difference between CF and magnetic resonance-ultrasound fusion in terms of cancer detection rates. For the experienced operators, we recommend lesions that are longer than 5 mm can be sampled using CF, an inexpensive and faster technique.